Supriya Lifescience Ltd. announced the outcome of its Board Meeting held on February 09, 2026. The Board approved the Unaudited Financial Results for the Quarter and nine months ended December 31, 2025. Key decisions included the reappointment of Dr. Neelam Yashpal Arora and the appointments of Mr. Manish Panchal and Mr. Kothandaraman Hari as Additional Independent Directors. The company also reported strong revenue performance in the nine-month period ending December 31, 2025.
Outcome of Board Meeting on February 09, 2026
The Board of Directors of Supriya Lifescience Limited convened on Monday, February 09, 2026, and approved several significant items, including the financial performance metrics and changes in the directorate.
Unaudited Financial Results Review
The Board reviewed and approved the Unaudited Financial Results for the Quarter and nine months ended December 31, 2025. These results were accompanied by the Limited Review Report from the Statutory Auditors.
Key Financial Highlights (Nine Months Ended 31-12-2025 vs. Previous Year)
The standalone unaudited results show the following key movements for the nine months ended December 31, 2025 (compared to 31-12-2024):
- Total Income: Increased from ₹5,192.16 million (31-12-2024) to ₹5,593.57 million.
- Profit Before Tax (PBT): Stood at ₹1,826.50 million for the nine months ended 31-12-2025, compared to ₹1,844.20 million in the previous corresponding period.
- Profit After Tax (PAT) from Continuing Operations: Reported at ₹1,348.92 million for the nine months ended 31-12-2025, against ₹1,375.76 million previously.
- Earnings Per Share (Basic and Diluted) for Continuing Operations: Declined slightly to ₹16.76 (per share) for the nine months ended 31-12-2025, down from ₹17.07.
The figures reflect a quarter where Exceptional Items amounted to a loss of (₹4.58 million), which has been attributed in the notes to developments related to the consolidation of New Labour Codes by the Government of India.
Changes in Directorate Structure
The Board also approved key changes related to Independent Directors:
- Re-appointment of Dr. Neelam Yashpal Arora (DIN: 01603068): Re-appointed as Non-Executive Independent Woman Director for a second term of 5 consecutive years, effective from March 25, 2026, to March 24, 2031, subject to shareholder approval. Dr. Arora possesses over 31 years of experience in education, commerce, and law.
- Appointment of Mr. Manish Panchal (DIN: 08431492): Appointed as Additional Independent Director effective February 09, 2026, to February 08, 2031. Mr. Panchal is a Business Leader with over 32 years of cross-industry experience in sectors including Chemicals, Pharma, and Medical Devices, and is active in Investment Banking.
- Appointment of Mr. Kothandaraman Hari (DIN: 08901674): Appointed as Additional Independent Director effective February 09, 2026, to February 08, 2031. Mr. Hari is a capital markets professional with over 28 years of experience, notably contributing to the growth of the National Stock Exchange of India (NSE).
All appointments are subject to the subsequent approval of the shareholders.
Reconstitution of Board Committees
The Board also approved the reconstitution of the following committees, effective from the date of the meeting:
Audit Committee
- Chairman: Mr. Hari K.
- Members: Dr. Ganapati Dadasaheb Yadav, Dr. Satish Waman Wagh, and Mr. Manish Panchal.
Nomination and Remuneration Committee
- Chairman: Mr. Hari K.
- Members: Dr. Sunil Subhash Bhagwat and Mr. Manish Panchal.
Stakeholders’ Relationship Committee
- Chairman: Mr. Manish Panchal.
- Members: Dr. Saloni Satish Wagh and Dr. Satish Waman Wagh.
The Board Meeting commenced at 03:00 p.m. and concluded at 05:00 p.m. on the specified date.
Source: BSE
